Literature DB >> 18078997

Structural characterization of a mutated, ADCC-enhanced human Fc fragment.

Vaheh Oganesyan1, Melissa M Damschroder, William Leach, Herren Wu, William F Dall'Acqua.   

Abstract

We report here the three-dimensional structure of a human Fc fragment engineered for enhanced antibody dependent cell mediated cytotoxicity (ADCC). The triple mutation S239D/A330L/I332E ('3M') was introduced into the C(H)2 portion of a human immunoglobulin G1 (IgG1) Fc. These three substitutions typically result in an about 10-100-fold increase in human IgG1 binding to human Fc gamma RIIIA (CD16). The recombinantly produced Fc/3M fragment was crystallized and its structure solved at a resolution of 2.5A using molecular replacement. No dramatic structural changes were observed in Fc/3M when compared with unmutated human Fc fragments. However, we found that the relative positions of its C(H)2 domains allowed for an unusually 'open' conformation of the entire fragment. Although this particular structural feature could be due to crystallization artifacts or intrinsic variability, we propose that molecular mechanisms at the basis of the enhanced interaction between Fc/3M and CD16 could include enhanced Fc openness as well as the introduction of additional hydrophobic contacts, hydrogen bonds and/or electrostatic interactions at the corresponding interface. The existence of a more pronounced cleft between the two Fc chains as well as of repulsive, electrostatic intra-chain interactions may also account in part for the decreased thermostability of both Fc/3M and a 3M-modified humanized anti-human EphA2 IgG1 when compared with their respective unmutated counterparts.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18078997     DOI: 10.1016/j.molimm.2007.10.042

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  37 in total

1.  Crystallization and preliminary X-ray diffraction analysis of the complex of a human anti-ephrin type-A receptor 2 antibody fragment and its cognate antigen.

Authors:  Vaheh Oganesyan; Melissa M Damschroder; Sandrina Phipps; Susan D Wilson; Kimberly E Cook; Herren Wu; William F Dall'Acqua
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2010-05-29

2.  Aglycosylated immunoglobulin G1 variants productively engage activating Fc receptors.

Authors:  Stephen L Sazinsky; René G Ott; Nathaniel W Silver; Bruce Tidor; Jeffrey V Ravetch; K Dane Wittrup
Journal:  Proc Natl Acad Sci U S A       Date:  2008-12-12       Impact factor: 11.205

3.  Engineering upper hinge improves stability and effector function of a human IgG1.

Authors:  Boxu Yan; Daniel Boyd; Timothy Kaschak; Joni Tsukuda; Amy Shen; Yuwen Lin; Shan Chung; Priyanka Gupta; Amrita Kamath; Anne Wong; Jean-Michel Vernes; Gloria Y Meng; Klara Totpal; Gabriele Schaefer; Guoying Jiang; Bartek Nogal; Craig Emery; Martin Vanderlaan; Paul Carter; Reed Harris; Ashraf Amanullah
Journal:  J Biol Chem       Date:  2011-12-27       Impact factor: 5.157

4.  Hsp90 is an essential regulator of EphA2 receptor stability and signaling: implications for cancer cell migration and metastasis.

Authors:  Balasubramaniam Annamalai; Xueguang Liu; Udhayakumar Gopal; Jennifer S Isaacs
Journal:  Mol Cancer Res       Date:  2009-06-30       Impact factor: 5.852

5.  Insertion of scFv into the hinge domain of full-length IgG1 monoclonal antibody results in tetravalent bispecific molecule with robust properties.

Authors:  Binyam Bezabeh; Ryan Fleming; Christine Fazenbaker; Haihong Zhong; Karen Coffman; Xiang-Qing Yu; Ching Ching Leow; Nerea Gibson; Susan Wilson; C Kendall Stover; Herren Wu; Changshou Gao; Nazzareno Dimasi
Journal:  MAbs       Date:  2017 Feb/Mar       Impact factor: 5.857

6.  Decreased Fc receptor expression on innate immune cells is associated with impaired antibody-mediated cellular phagocytic activity in chronically HIV-1 infected individuals.

Authors:  Anne-Sophie Dugast; Andrew Tonelli; Christoph T Berger; Margaret E Ackerman; Gaia Sciaranghella; Qingquan Liu; Magdalena Sips; Ildiko Toth; Alicja Piechocka-Trocha; Musie Ghebremichael; Galit Alter
Journal:  Virology       Date:  2011-05-12       Impact factor: 3.616

7.  Explaining the non-newtonian character of aggregating monoclonal antibody solutions using small-angle neutron scattering.

Authors:  Maria Monica Castellanos; Jai A Pathak; William Leach; Steven M Bishop; Ralph H Colby
Journal:  Biophys J       Date:  2014-07-15       Impact factor: 4.033

8.  Immunoglobulin G1 Fc domain motions: implications for Fc engineering.

Authors:  Martin Frank; Ross C Walker; William N Lanzilotta; James H Prestegard; Adam W Barb
Journal:  J Mol Biol       Date:  2014-02-09       Impact factor: 5.469

9.  Antitumor Efficacy of Anti-GD2 IgG1 Is Enhanced by Fc Glyco-Engineering.

Authors:  Hong Xu; Hongfen Guo; Irene Y Cheung; Nai-Kong V Cheung
Journal:  Cancer Immunol Res       Date:  2016-05-16       Impact factor: 11.151

10.  Engineering a monomeric Fc domain modality by N-glycosylation for the half-life extension of biotherapeutics.

Authors:  Tetsuya Ishino; Mengmeng Wang; Lidia Mosyak; Amy Tam; Weili Duan; Kristine Svenson; Alison Joyce; Denise M O'Hara; Laura Lin; William S Somers; Ronald Kriz
Journal:  J Biol Chem       Date:  2013-04-24       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.